Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 6, 2009, Pages 1030-1037

  Kayali, Zeid ^a   Herring, Jason ^a   Baron, Pedro ^a   Franco, Edson ^a   Ojogho, Okechukwu ^a   Smith, Jason ^a   Watkins, Gregory ^a   Smith, Douglas ^a   Lamin, Victor ^a   Hoang, Thanh ^a   Sharma, Rajiv ^a   Mathahs, Meleah ^b   Sowers, Lawrance ^a   Brown, Kyle E ^b   Schmidt, Warren N ^b  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; L Arginine; Nitric oxide; Refractory ascites; Renal failure

Indexed keywords

ARGINASE 1; ARGININE; NITRIC OXIDE;

ADULT; ARTICLE; ASCITES; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HEPATORENAL SYNDROME; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLANCHNIC BLOOD FLOW; VASODILATATION;

ADULT; ARGINASE; ARGININE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HEPATORENAL SYNDROME; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 66549098913     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05757.x     Document Type: Article

References (49)

1. Llach J, Gines P, Arroyo V et al. Value of arterial-pressure, endogenous vasoactive systems, and renal-function in cirrhotic-patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988 94 : 482 7.
2. Gines P, Martin PY, Nierderberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int. Suppl. 1997 61 : S77 S82.
3. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003 362 : 1819 27.
4. Ruiz-del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005 42 : 439 47.
5. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N. Engl. J. Med. 1982 307 : 1552 7.
6. Gines A, Escorsell A, Gines P et al. Predictive factors, and prognosis of the hepatorenal-syndrome in cirrhosis with ascites. Gastroenterology 1993 105 : 229 36.
7. Albornoz L, Motta A, Alvarez D et al. Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relationship with hemodynamic disturbances. J. Hepatol. 2001 35 : 452 6.
8. Guarner C, Soriano G, Tomas A et al. 1993 18 : 1139 43.
9. Hori N, Okanoue T, Mori T et al. Endogenous nitric oxide production is augmented as the severity advances in patients with liver cirrhosis. Clin. Exp. Pharmacol. Physiol. 1996 23 : 30 5.
10. Sarela AI, Mihaimeed FMA, Batten JJ, Davidson BR, Mathie RT. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 1999 44 : 749 53.
11. Woitas RP, Heller J, Stoffel-Wagner B, Spengler U, Sauerbruch T. Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis. Hepatology 1997 26 : 858 64.
12. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis - a role for nitric-oxide. Lancet 1991 337 : 776 8.
13. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J. Hepatol. 1997 26 : 75 80. (Pubitemid 27072607)
14. Campillo B, Bories PN, Benvenuti C, Dupeyron C. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J. Hepatol. 1996 25 : 707 14.
15. Coskun U, Ozenirler S, Sancak B, Bukan N. Serum and ascitic fluid nitrate levels in patients with cirrhosis. Clin. Chim. Acta 2001 306 : 127 32.
16. Curgunlu A, Vural P, Canbaz M, Erten N, Karan MA, Tascioglu C. Plasma nitrate/nitrite and endothelin-1 in patients with liver cirrhosis. J. Clin. Lab. Anal. 2005 19 : 177 81.
17. Galley HF, Coomansingh D, Webster NR, Brunt PW. Nitric oxide synthase activity is increased in relation to the severity of liver dysfunction. Clin. Sci. 1998 95 : 355 9.
18. Heller J, Kristeleit H, Brensing KA, Woitas RP, Spengler U, Sauerbruch T. Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand. J. Gastroenterol. 1999 34 : 297 302. (Pubitemid 29193003)
19. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric-oxide. Annu. Rev. Pharmacol. Toxicol. 1990 30 : 535 60.
20. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric-oxide from L-Arginine - a pathway for the regulation of cell-function and communication. Biochem. Pharmacol. 1989 38 : 1709 15.
21. Moncada S, Higgs A. Mechanisms of disease - the L-Arginine nitric-oxide pathway. N. Engl. J. Med. 1993 329 : 2002 12.
22. La Villa G, Barletta G, Pantaleo P et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001 34 : 19 27. (Pubitemid 32591478)
23. Spahr L, Martin PY, Giostra E et al. Acute effects of nitric oxide synthase inhibition on systemic, hepatic, and renal hemodynamics in patients with cirrhosis and ascites. J. Investig. Med. 2002 50 : 116 24.
24. Thiesson HC, Skott O, Jespersen B, de Muckadell OBS. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am. J. Gastroenterol. 2003 98 : 180 6.
25. Limberg B, Kommerell B. Correction of Altered Plasma Amino-Acid Pattern in Cirrhosis of the Liver by. Somatostatin. Gut 1984 25 : 1291 5.
26. Vilstrup H, Bucher D, Krog B, Damgard SE. Elimination of infused amino-acids from plasma of control subjects and of patients with cirrhosis of the liver. Eur. J. Clin. Invest. 1982 12 : 197 202. (Pubitemid 12082472)
27. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J. Nutr. 2007 137 : 1616S 1620S. (Pubitemid 46855520)
28. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996 23 : 164 76.
29. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007 56 : 1310 18.
30. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, Mchutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential-diagnosis of ascites. Ann. Intern. Med. 1992 117 : 215 20.
31. Silva MA, Mirza DF, Buckels JAC et al. Arginine and urea metabolism in the liver graft: a study using microdialysis in human orthotopic liver transplantation. Transplantation 2006 82 : 1304 11.
32. Loethar T, Andreas RH. Renal Function- estimation of glomerular filtration rate. Clin. Chem. Lab. Med. 2006 44 : 1205 302.
33. Nissim I, Yudkoff M, Terwilliger T, Segal S. Rapid-determination of [guanidino-N-15] arginine in plasma with gas-chromatography mass-spectrometry - application to human metabolic studies. Anal. Biochem. 1983 131 : 75 82.
34. Steven L, Coresh J, Greene T, Levey A. Assessing kidney function-measured and estimated glomerular filtration rate. NEJM 2006 354 : 2473 83.
35. Huynh NN, Chin-Dusting J. Amino acids, arginase and nitric oxide in vascular health. Clin. Exp. Pharmacol. Physiol. 2006 33 : 1 8.
36. Lee J, Ryu H, Ferrante RJ, Morris SM Jr., Rattan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc. Natl. Acad. Sci. USA 2003 100 : 4843 8.
37. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002 122 : 1658 76.
38. Garcia-Estan J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin. Sci. 2002 102 : 213 22.
39. Atucha NM, GarciaEstan J. Intrarenal alterations in experimental liver cirrhosis. News Physiol. Sci. 1996 11 : 48 52.
40. Bosch-Marce M, Morales-Ruiz M, Jimenez W et al. Increased renal expression of nitric oxide synthase type III in cirrhotic rats with ascites. Hepatology 1998 27 : 1191 9.
41. Criado M, Flores O, Ortiz MC et al. Elevated glomerular and blood mononuclear lymphocyte nitric oxide production in rats with chronic bile duct ligation: role of inducible nitric oxide synthase activation. Hepatology 1997 26 : 268 76.
42. Martin PY, Ohara M, Gines P et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J. Clin. Invest. 1998 101 : 235 42.
43. Xu LM, Carter EP, Ohara M et al. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am. J. Physiol. Renal. Physiol. 2000 279 : F1110 15.
44. Hon WN, Lee HC, Lee KH. Effect of hemodialysis on plasma nitric oxide levels. Artif. Organs 2000 24 : 387 90.
45. Caregaro L, Menon F, Angeli P et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch. Intern. Med. 1994 154 : 201 5.
46. Papadakis MA, Arieff AI. Unpredictability of clinical-evaluation of renal-function in cirrhosis - prospective-study. Am. J. Med. 1987 82 : 945 52.
47. Morris CR, Morris SM, Hagar W et al. Arginine therapy - a new treatment for pulmonary hypertension in sickle cell disease? Am. J. Respir. Crit. Care Med. 2003 168 : 63 9.
48. Hein TW, Zhang CH, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003 17 : 2328 30.
49. Berkowitz DE, White R, Li DC et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003 108 : 2000 6.